Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29106604 | 0.96 | MAPT (0.66) | MAPTALDH1A1L3MBTL1KMT2ANPC1 | |
| SCHEMBL85553 | 0.87 | MAPT (0.65) | MAPTALDH1A1L3MBTL1KMT2ANPC1 | |
| SCHEMBL17980007 | 0.86 | NPC1 (0.69) | MAPTALDH1A1L3MBTL1KMT2ANPC1 | |
| SCHEMBL30168150 | 0.85 | ALDH1A1 (0.67) | MAPTALDH1A1L3MBTL1KMT2ALMNA | |
| SCHEMBL10674588 | 0.85 | ALDH1A1 (0.67) | MAPTALDH1A1L3MBTL1KMT2ALMNA | |
| SCHEMBL16730430 | 0.84 | MAPT (0.72) | MAPTALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL11456402 | 0.82 | MAPT (0.62) | MAPTALDH1A1KMT2ANPC1LMNA | |
| SCHEMBL4467318 | 0.81 | MAPT (0.55) | MAPTALDH1A1L3MBTL1KMT2ANPC1 | |
| SCHEMBL4472308 | 0.81 | MAPT (0.56) | MAPTALDH1A1L3MBTL1KMT2ANPC1 | |
| SCHEMBL14192526 | 0.81 | ALDH1A1 (0.73) | MAPTALDH1A1L3MBTL1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815833-B2 | Pyridine derivative and medical use thereof | CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD. (CN) | 2017-11-14 | — | — | US | disclosed |
| EP-3072892-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | Chengdu Easton Biopharmaceuticals Co., Ltd. (CN) | 2016-09-28 | — | — | EP | disclosed |
| US-20160244440-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | Zhejiang Yatai Pharmaceutical Co., Ltd. (CN) | 2016-08-25 | — | — | US | disclosed |
| WO-2015070809-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | 成都苑东药业有限公司 | 2015-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244440-A1 | PYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | PEPD, F2, XDH | MAPT 4645/4885ALDH1A1 905/4885L3MBTL1 4779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.